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Background: Leptin, produced mainly by white adipose tissue, is a hormone that promotes vascular smooth
muscle cell (VSMC) migration and proliferation, a process involved in the pathophysiology of atherosclerosis. Leptin
expression in human coronary artery smooth cell (HCASMC) is induced by hypoxia. However, our understanding of
the process of atherosclerosis in HCASMC is only emerging. Since the mechanisms by which hypoxia regulates
leptin in HCASMC are as yet unknown, this study aims to investigate the mechanics of molecular regulation of
leptin expression in HCASMC under hypoxia. We subjected cultured HCASMCs to hypoxia for varying periods of
time. Through use of different signal pathway inhibitors, we were able to sort out and identify the pathway
through which hypoxia-induced leptin expression occurs.
Results: Leptin mRNA and protein levels increased after 2.5% hypoxia for 2-to-4 hours, with earlier expression of
angiotensin II (AngII) and reactive oxygen species (ROS). The addition before hypoxia of the c-Jun N-terminal kinase
(JNK) pathway inhibitor (SP600125), JNK small interfering RNA (siRNA), AngII receptor blockers (ARBs; losartan), or
N-acetyl-L-cysteine (NAC, an ROS scavenger), had the effect of inhibiting JNK phosphorylation and leptin expression.
Gel shift assay and luciferase promoter study showed that leptin/activator protein 1 (AP-1) binding and transcriptional
activity to the leptin promoter increased after hypoxia, and SP600125, JNK siRNA, losartan, and NAC abolished the
binding and transcriptional activity induced by hypoxia. The use of SP600125, JNK siRNA, losartan, and NAC effectively
inhibited the binding and transcriptional activity induced by hypoxia. Migration and proliferation, ROS generation, and
the presence of leptin in the nuclei of HCASMCs also increased under hypoxia.
Conclusion: Hypoxia in HCASMCs increases leptin expression through the induction of AngII, ROS, and the JNK
pathway to enhance atherosclerosis in HCASMCs.
Keywords: Leptin, Human coronary artery smooth muscle cell, Hypoxia, Angiotensin II, c-Jun N-terminal kinase pathwayBackground
Leptin is a hormone that was discovered in 1994, the
product of research that has brought significant ad-
vances in the understanding of cardiovascular diseases
(CVDs), obesity, and the metabolic syndrome [1]. Apart
from its function as a regulator of energy expenditure,
leptin also serves other roles, among them, leptin func-
tions as a producer of a number of important chemical* Correspondence: m004401@yahoo.com.tw
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unless otherwise stated.messengers [2]. The primary functions of leptin include
appetite and energy balance, angiogenesis, insulin secre-
tion, blood pressure control, vascular hemostasis, inflam-
mation and immune response, and metabolic regulation
[3-9]. Its production improves endothelial function, pro-
motes angiogenesis, and reduces hypertension, athero-
sclerosis and inflammation. Some of Leptin’s peripheral
effects, however, are negative, including the stimulation of
vascular inflammation, oxidative stress, and vascular
smooth muscle cell (VSMC) hypertrophy [3-16]. Several
studies have shown an independent relationship between
high leptin levels and atherosclerosis, myocardial infarc-
tion, stroke, and coronary artery intimal hyperplasia, sug-
gesting that leptin may increase risks of CVDs [17,18].is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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in increased by hypoxic conditions in various tissues
such as placenta, pancreas, human skin dermal fibro-
blasts, adipocytes, and heart [4,19-22]. In fact, leptin is
the gene most induced under hypoxia in human coron-
ary arterial smooth muscle cell (HCASMC) [23]. Func-
tional analyses of the leptin promoter reveal that
hypoxic response elements mediate transcriptional acti-
vation by hypoxia. Furthermore, hypoxia in the adipo-
cyte of white adipose tissue (a major site of leptin
production) has been found to upregulate the secretion
of a number of inflammation-related leptins [21]. Other
studies have indicated that leptin is able to stimulate re-
active oxygen species (ROS) generation in the cardiovas-
cular system [24,25]. In addition, exogenous addition or
stress-induced secretion of angiotensin II (AngII), a
proatherogenic cytokine and a local mediator of in-
flammation, increases leptin synthesis in adipocytes and
VSMCs [26,27].
Despite these findings, however, our understanding of
the process of atherosclerosis in HCASMCs is only just
emerging. To address the lack of detailed data in this
field, this study aims to investigate the effect of hypoxia
on leptin expression in HCASMCs. In particular, we will
examine two related questions: whether hypoxia-induced
pro-inflammatory cytokine (ex: AngII) secretion and
ROS generation could trigger the induction of leptin,
and whether this process is associated with the migra-
tion and proliferation of HCASMCs under hypoxia. This
study will also investigate the signal pathways and mo-
lecular mechanisms mediating the expression of leptin
by hypoxia in HCASMCs. Ultimately, a better under-
standing of the detailed mechanisms of leptin expression
in hypoxic HCASMCs will provide us new insight in
prevention and therapy for leptin-related atherosclerosis,




HCASMCs were obtained from Promo Cell GmbH
(Heidelberg, Germany). The cells were cultured in growth
medium supplemented with 10% fetal bovine serum, 100
U/ml penicillin, and 100 μg/ml streptomycin, all at 37°C
in a humidified atmosphere of 5% CO2. Cells were grown
to 90% confluence in 10 cm2 culture dishes and were sub-
cultured in the ratio of 1:2. The enriched HCASMCs were
then subjected to hypoxia.
Hypoxia settings for HCASMC culture
Hypoxia was achieved by adding medium pre-equilibrated
with nitrogen gas to the cells prior to incubation in a Plexi-
glas chamber purged with water-saturated nitrogen gas
by an oxygen controller (PROOX model 110; BioSpherix,Ltd.; Redfield, NY). The partial pressure of oxygen (pO2)
of the culture medium under hypoxia was monitored
using an ISO2 dissolved oxygen meter (World Precision
Instruments, Inc.; Sarasota, FL). Hypoxia culture media
(BioSpherix C-chamber) was used with mixed air in and
out controlled by a BioSpherix PROOX incubator. Hyp-
oxia settings were as follows: 1) 10% O2, 5% CO2, and
85% N2; 2) 5% O2, 5% CO2, and 90% N2; 3) 2.5% O2, 5%
CO2, and 92.5% N2. The use of a lower oxygen concen-
tration (1%) was also tested, but the HCASMCs did not
survive under such severe hypoxia. Hypoxia was applied
for different hours. Researchers did not change the cul-
ture media throughout the experiment.
Antibodies and reagents
We purchased recombinant leptin protein from Pepro-
Tech (Rocky Hill, NJ). Polyclonal antibodies against lep-
tin and anti-AngII antibodies were obtained from Santa
Cruz Biotechnology (Santa Cruz, CA). Polyclonal anti-
bodies against c-Jun N-terminal kinase (JNK) and mono-
clonal antibodies (mAbs) against phospho-JNK were
obtained from Cell Signaling (Beverly, MA, USA). PD98059,
SB203580, and SP600125 were purchased from Calbiochem
(San Diego, CA). Monoclonal anti-α-tubulin antibody and
other reagents were obtained from Sigma (St. Louis, MO).
The roles of JNK, p38 mitogen-activated protein kinase
(MAPK), and extracellular signal-regulated kinase (ERK)
in hypoxia-induced leptin expression were determined by
pretreatment of the HCASMCs with 25 μM SP600125,
3 μM SB203580, or 10 μM PD98059 before hypoxia.
SP600125 is a potent, cell-permeable, selective, and revers-
ible inhibitor of JNK. SB203580 is a highly specific, cell-
permeable inhibitor of p38 MAPK. PD98059 is a specific
and potent inhibitor of the ERK pathway. To examine
the effect of ARBs (AngII type 1 receptor blockers),
HCASMCs were treated with 100 nM losartan (Merck &
Co., Inc., Whitehouse Station, NJ). N-Acetyl-L-cysteine
(NAC; a free radical scavenger), and Dp44mT (2,2′-dipyri-
dyl-N,N-dimethylsemicarbazone; a ROS generator), and
Anisomycin (a stimulator of JNK MAPK) were purchased
from Calbiochem. In the respective experiments, cells
were treated with 30 nM of Dp44mT, 500 μM of NAC,
and 20 μM of Anisomycin.
RNA isolation and reverse transcription
Total RNA was isolated from cells using a single-step
acid guanidinium thiocyanate/phenol/chloroform extrac-
tion method. Total RNA (1 μg) was incubated with 200 U
of Moloney-Murine Leukemia Virus reverse transcriptase
in a buffer containing a final concentration of 50 mmol/L
Tris-Cl (pH 8.3), 75 mmol/L KCl, 3 mmol/L MgCl2, 20 U
of RNase inhibitor, 1 μmol/L poly-dT oligomer, and
0.5 mmol/L of each dNTP in a final volume of 20 μL.
Primers were designed for detection of leptin gene
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TT-3′; reverse: 5′-AGCCACAAGAATCCGCACAGG-
3′). The reaction mixture was incubated at 42°C for
1 hour and then at 94°C for 5 minutes to inactivate the
enzyme. A total of 80 μL of diethyl pyrocarbonate treated
water was added to the reaction mixture before storage
at −70°C.
Real-time quantitative PCR
A Lightcycler (Roche Diagnostics, Mannheim, Germany)
was used for real-time PCR. cDNA was diluted to a ra-
tion of 1 in 10 with nuclease-free water. We used 2 μL
of the solution for the Lightcycler SYBR-Green master-
mix (Roche Diagnostics, Basel, Switzerland): 0.5 μmol/L
primer, 5 mmol/L MgCl2, and 2 μL Master SYBR-Green
in nuclease free water in a final volume of 20 μL. The
initial denaturation phase for a specific gene was 5 min
at 95°C followed by an amplification phase as detailed
below: denaturation at 95°C for 10 sec; annealing at 63°C
for 7 sec; elongation at 72°C for 8 sec; detection at 79°C
and for 45 cycles. Amplification, fluorescence detection,
and post-processing calculation were performed using the
Lightcycler apparatus. Individual PCR products were ana-
lyzed for DNA sequence to confirm the purity of the
product.
Western blot analysis
After harvesting HCASMCs by scraping, we centrifuged
(300 × g) the sample for 10 min at 4°C. The pellet was
resuspended and homogenized in Lysis Buffer (Promega
Corp., Madison, WI), centrifuging at 10,600 × g for
20 minutes. Bio-Rad Protein Assay was used to measure
the protein content. Equal amounts of protein (15 μg)
were loaded into a 12.5% sodium dodecyl sulfate (SDS)-
polyacrylamide mini gel, followed by electrophoresis.
Proteins were electroblotted onto nitrocellulose. The blots
were incubated overnight in Tris-buffered saline contain-
ing 5% milk to block nonspecific binding of the antibody.
Proteins of interest were revealed with specific antibodies
as indicated (1:1000 dilution) for 1 hour at room tem-
perature, followed by incubation with a 1:5000 dilution of
horseradish peroxidase-conjugated polyclonal anti-rabbit
antibody for 1 hour at room temperature. The membrane
was then detected with an enhanced chemiluminescence
detection system (Amersham, Buckinghamshire, England).
Equal protein loading of the samples was further verified
by staining mouse anti-tubulin mAbs. All Western blots
were quantified using densitometry.
RNA interference
HCASMCs were transfected with JNK-, leptin- and hyp-
oxia inducible factor-1α (HIF-1α)-annealed small inter-
fering RNA (siRNA; Dharmacon; Lafayette, CO). JNK1,
leptin, or HIF-1α siRNAs are target-specific 19- to 21-ntsiRNAs designed to knock down gene expression. The
JNK1 siRNA sequences were 5′-CGUGGAUUUAUGG
UCUGUGdTdT (sense) and 5′-CACAGACCAUAAAUC
CACGdTdT (antisense). The leptin siRNA sequences
were 5′-GCAGATAGCTCATGACCTGTT (sense) and
5′-AACAGGTCATGAGCTATCTGC (antisense). The
HIF-1α siRNA sequences were 5′-UUACUGAGUUGA
UGGGUUA (sense) and 5′-UAACCCAUCAACUCAG
UAA (antisense). As a negative control, a control siRNA
was used. HCASMCs were transfected with siRNA oli-
gonucleotides, using Effectene transfection reagent ac-
cording to the manufacturer’s instructions (Qiagen;
Valencia, CA).
Enzyme-linked immunosorbent assay (ELISA) for AngII
and leptin
The level of AngII and leptin were measured by using a
quantitative sandwich enzyme immunoassay (SPI-BIO;
Massy, France), using a specific anti-AngII and anti-
leptin antibodies, as previously described [28]. Condi-
tioned medium from HCASMCs subjected to hypoxia
and those from control cells were collected for AngII
and leptin measurement. Both the intra-assay and the
inter-assay coefficient of variance were less than 10%.
Electrophoretic mobility shift assay (EMSA)
Nuclear protein concentrations from cells were deter-
mined by Bio-rad protein assay. Consensus and control ol-
igonucleotides (Santa Cruz Biotechnology Inc., CA) were
labeled by polynucleotides kinase incorporation of [γ-32P].
After radiolabeling the oligonucleotide, we mixed the nu-
clear extracts (4 μg of protein in 2 μl of nuclear extract)
with 20 pmol of the appropriate [γ-32P]-labeled consensus
or mutant oligonucleotide in a total volume of 20 μl for
30 minutes at room temperature. The consensus oligo-
nucleotide sequence of activator protein 1 (AP-1) was 5′-
CGCTTGATGACTCAGCCGGAA-3′. The AP-1 mutant
oligonucleotide sequence was 5′-CGCTTGATGACTTG
GCCGGAA-3′. The samples were then resolved on a 4%
polyacrylamide gel. We used autoradiography to image
dried and imaged gels. In each case controls were per-
formed with mutant oligonucleotides or cold oligonu-
cleotides to compete with labeled sequences.
Luciferase reporter DNA construction, transient
transfection, and luciferase assay
A human leptin promoter construct (−866/+35) with
specific forward and reverse primers was generated and
amplified as follows. The amplified product was digested
with the restriction enzymes MluI and BglII and ligated
into the pGL3-basic luciferase plasmid vector (Promega)
digested with the same enzymes. The leptin promoter con-
tains leptin-binding sites for AP-1 (CA) at position −596
to −595. We also changed the mutant sequence at
Chiu et al. Journal of Biomedical Science  (2015) 22:5 Page 4 of 14position −596 to −595 from CA to TG. For the mu-
tant, the leptin binding sites were mutated using a mu-
tagenesis kit (Stratagene, La Jolla, CA). Site-specific
mutations were confirmed by DNA sequencing. Plas-
mids were transfected into HCASMCs using a low
pressure-accelerated gene gun (Bioware Technologies,
Taipei, Taiwan) essentially following the protocol from
the manufacturer. Test plasmid at 2 μg and control
plasmid (pGL4-Renilla luciferase) 0.02 μg was co-
transfected with gene gun in each well, and then re-
placed by normal culture medium. Following 2 hours
of hypoxia, cell extracts were prepared using Dual-
Luciferase Reporter Assay System (Promega) and mea-
sured for dual luciferase activity by luminometer (Glomax,
Progega).
Measurement of intracellular ROS
Intracellular reactive oxygen species (ROS) generation was
measured using 5-(and-6)-chloromethyl-2′, 7′- dichloro-
fluorescein diacetate, acetyl ester (CM-H2DCFDA; Invitro-
gen, Carlsbad, CA), a cell-permeant indicator for ROS.
We subjected confluent cells to serum starvation for
24 hours in preparation for experimentation. Starved cells
were then treated with 2.5% hypoxia and NAC for 5 mi-
nutes at 37°C and then imaged by inverted fluorescence
microscopy. ROS production was measured using the cell
permeant probe 2′-7′-dichloro- dihydrofluorescin diace-
tate, which passively diffuses into cells in which intracellular
esterase cleaves the acetate groups to form the imperme-
able 2′, 7′-dichlorofluorescin that remains trapped within
the cell. After hypoxia treatment, we collected cells by
trypsinization and resuspended them in phosphate-
buffered saline medium. The ROS assay was performed
according to the manufacturer’s instruction (Invitrogen,
Eugene, OR). We used fluorescence microscopy to detect
the green fluorescence.
Migration assay
We determined the migration activity of HCASMCs
using the growth factor-reduced Matrigel invasion sys-
tem (Becton Dickinson, Franklin Lakes, NJ) following
manufacturer’s protocol. We then seeded the Matrix gel
(Chemicon International, Inc., Temecula, CA) with 5 × 104
cells. Cells were then incubated at 37°C for 4 hours, with
or without hypoxia. Three different phase-contrast micro-
scopic high-power fields per well were photographed. The
migratory cells with positive stain were counted by an ob-
server blind to the experiment.
Proliferation assay
We determined the proliferation of HCASMCs using
[3H]Thymidine incorporation into the HCASMCs. Cells
were seeded on ViewPlate (Packard Instrument, Meriden,
CT) at a density of 5 × 103 cells/well in a serum-freemedium. Thymidine uptake was studied by addition of
500 nCi/ml [3H]Thymidine (Perkin Elmer, Boston, MA)
for 2 to 4 hours, with or without hypoxia. Cells were
washed twice with PBS. We studied nonspecific uptake in
the presence of 10 μM cytochalasin B which was then sub-
tracted from the measured value. MicroScint-20 (50 μl)
was added, and the plate was read with Top Count (Pack-
ard Instrument).Statistical analysis
The data were expressed as mean ± SD. Statistical signifi-
cance was performed with analysis of variance (GraphPad
Software Inc., San Diego, CA). The Tukey-Kramer com-
parison test was used for pairwise comparisons between
multiple groups after the ANOVA. We denoted statistical
significance at a value of P < 0.05.Results
Hypoxia increases the expression of leptin in cultured
HCASMCs
We used different settings of hypoxia (10%, 5%, and
2.5%) for 4 hours as we laid out in the methods section
(Additional file 1: Figure S1). We noted the greatest ef-
fect on the leptin protein expression at 2.5% hypoxia for
4 hours, as compared with 10% and 5% hypoxia. There-
fore, we used 2.5% hypoxia for further analysis. Sub-
jected to 2.5% hypoxia, the protein levels of leptin
increased gradually and reached a peak after 4 hours
(Figures 1A and B). The mRNA expression levels of lep-
tin also reached their maximum after 2 hours and then
decreased gradually (Figure 1C).Hypoxia increases the expression of leptin in cultured
HCASMCs through the JNK pathway
We used different signal pathway inhibitors to identify
the signal transduction pathways of leptin under hypoxia
(PD98059: ERK pathway inhibitor, SP600125: JNK in-
hibitor, and SB203580: P38 inhibitor). The JNK inhibitor
(SP600125) produced the most immediately evident effect
on Leptin expression, with the siRNA of JNK1 and NAC
achieving the same effect (Figures 2A and B; Additional
file 2: Figure S2). The solvent of the inhibitors (dimethyl
sulfoxide; DSMO) did not inhibit hypoxia-induced expres-
sion of leptin. The exogenous addition of Dp44mT (an
ROS generator) under normoxia also increased leptin ex-
pression (Figure 2A and B). We also found that JNK pro-
tein phosphorylation increased to its maximal level at
2 hours after exposure to 2.5% hypoxia, after which it
gradually declined. SP600125 and JNK siRNA could effect-
ively block phosphorylation of JNK protein. In addition,
phosphorylation of the JNK protein could also be sup-
pressed by NAC (Figures 2C and D).
Figure 1 Effect of 2.5% O2 hypoxia on leptin expression in
human coronary artery smooth muscle cells (HCASMCs).
(A and B) Leptin protein levels increased, reaching a peak after
4 hours of 2.5% O2 hypoxia. We subjected HCASMCs to hypoxia for
2 to 8 hours. Total cell lysates were harvested and Western blot was
performed using anti-leptin antibody. Alpha-tubulin was used as a
protein loading control in each lane. *P < 0.01 vs. normoxia control
(n = 3). (C) Leptin mRNA level reached a peak after 2 h of 2.5% O2
hypoxia then declined. We used GAPDH as an internal control.
*P < 0.01 vs. normoxia control (n = 3).
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secretions in cultured HCASMCs
Under 2.5% hypoxia, the AngII level increased and
reached a peak after 1 hour, after which it began to de-
cline. This timing of peak-and-decline happened consid-
erably earlier than that of leptin levels, which reached
their peak after 4 hours (Figures 3A and B). The addition
of SP600125, losartan, and NAC before hypoxia sig-
nificantly decreased leptin secretion from HCASMCs
(Figure 3B). Exogenously added AngII (10 nM) also in-
creased the leptin protein expression to a similar degree
as 2.5% hypoxia (Figures 3C and D). The hypoxia-
induced increase in the leptin protein level could besuppressed by ARB (losartan: 100 nM) and the AngII
antibody (Figures 3C and D).
Hypoxia induces intracellular ROS formation
Intracellular ROS production increased after hypoxia for
1 hour (Figures 4A and B). Both Dp44mT (A ROS gen-
erator) and AngII achieved the same effects. NAC (an
ROS scavenger) and losartan were noted to be effective
in repressing hypoxia-induced intracellular ROS gener-
ation (Figure 4A and B).
Hypoxia increases the binding between leptin and AP-1
and enhances transcriptional activity to the promoter of
leptin in HCASMCs
Under 2.5% hypoxia, electrophoretic motility shift assays
(EMSA) revealed increased binding activity between
leptin and AP-1 (Figure 5A). This finding indicates that
applying hypoxia to HCASMCs may increase the inter-
action between leptin and AP-1, as well as leptin expres-
sion and leptin/AP-1-binding activity. In addition, the
binding between leptin and AP-1 could be effectively
inhibited by SP600125, losartan, and NAC.
We also used a luciferase reporter assay to identify the
genetic transcription activity of leptin in HCASMCs
under hypoxia (Figures 5B and C). We found that hyp-
oxia increased transcriptional activity of the leptin pro-
moter. Leptin mutants failed to manifest the same effect
as wild-type leptin under hypoxia. Exogenously added
AngII also increased the transcriptional activity of leptin
in HCASMCs. SP600125, NAC, and losartan suppressed
the transcriptional activity of leptin to HCASMCs.
Therefore, both exogenously added AngII and hypoxia-
induced AngII secretion resulted in leptin/AP-1 complex-
associated gene transcription in HCASMCs. We also
found that hypoxia-induced leptin expression may be in-
dependent to HIF-1α in HCASMCs. Because hypoxia-
induced leptin expression could not be inhibited by siRNA
of HIF-1α in our experiment (Additional file 3: Figure S3).
AngII, ROS, and the JNK pathway are involved in leptin
expression in HCASMCs under hypoxia
As shown in Figure 6, treatment with hypoxia, AngII, an
ROS generator (Dp44mT), and a JNK MAPK stimulator
(Anisomycin) increased leptin protein expression in
HCASMCs. AngII-induced leptin protein expression
could be inhibited by SP600125 and NAC. Dp44mT-
induced leptin protein expression could be inhibited by
SP600125. However, Anisomycin-induced leptin protein
expression could not be inhibited by losartan (ARB) or
NAC. These results imply that hypoxia-induced leptin
expression in HCASMCs is regulated through the JNK
pathway, with its earliest expression coming from treat-
ment with AngII, and then from ROS.
Figure 2 The JNK pathway mediates hypoxia-induced leptin expression in HCASMCs. (A and B) The c-Jun N-terminal kinase (JNK) inhibitor
(SP600125), JNK small interfering RNA (siRNA), and N-acetyl-L-cysteine (NAC; a ROS scavenger) all blocked hypoxia-induced leptin expression.
Exogenous addition of Dp44mT (an ROS generator; 30 nM)) under normoxia also increased leptin expression. We pretreated HCASMCs with an
extracellular signal-regulated kinase (ERK) pathway inhibitor (PD98059; 50 μM), a JNK inhibitor (SP600125; 25 μM), a p38 mitogen-activated protein
kinase (MAPK) inhibitor (SB203580; 3 μM), NAC (500 μM), or JNK1 siRNA prior to hypoxia for 4 hours. The HCASMCs were then harvested and
analyzed by western blotting using an anti-leptin antibody. The results were normalized to α-tubulin. *P < 0.01 vs. normoxia control. #P < 0.01 vs.
4 h (n = 3). (C and D) Phosphorylation of the JNK mediated hypoxia-induced leptin expression in HCASMCs, which was blocked by SP600125,
JNK1 siRNA, and NAC. HCASMCs were subjected to normoxia or hypoxia for different durations in the presence or absence of inhibitors. Cell
lysates were collected for western blot analysis, using antibody for total and phospho-JNK. T-JNK = total JNK. P-JNK = JNK phosphorylation.
*P < 0.01 vs. normoxia control. #P < 0.01 vs. 2 h (n = 3).
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We examined migration activity in order to test the ef-
fect of hypoxia on the function of HCASMCs. As shown
in Figure 7, treatment with hypoxia for 4 hours signifi-
cantly increased the migration activity of HCASMCs.
Pretreatment with SP600125, losartan, and leptin siRNAsignificantly blocked the induction of migration by
hypoxia in HCASMCs. The control siRNA did not in-
hibit the migration activity induced by hypoxia. In
addition, exogenous additions of AngII, Dp44mT, or
leptin also significantly increased the migration activ-
ity of HCASMCs.
Figure 3 Angiotensin II (AngII) mediates hypoxia-induced leptin expression in HCASMCs. (A and B) AngII and leptin were measured in cell
lysates and the culture medium by a quantitative, competitive Enzyme-linked immunosorbent assay (ELISA) using a specific anti-AngII and
anti-leptin antibodies. *P < 0.01 vs. normoxia control. #P < 0.01 vs. 4 h (n = 3). (C and D) Hypoxia-induced leptin expression was suppressed by
AngII antibody and losartan. Exogenous addition of AngII (under normoxia) also increased leptin expression. HCASMCs were subjected to
normoxia or hypoxia for 4 h and total cell lysates were immunoblotted with anti-leptin antibody. Alpha-tubulin was used as a protein loading
control in each lane. *P < 0.01 vs. normoxia control. #P < 0.01 vs. 4 h (n = 3).
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Hypoxia in HCASMCs increased cell proliferation after
2 to 4 hours; the increase was inhibited by SP600125,
losartan, leptin siRNA, and NAC (Figures 8). In addition,
exogenously added AngII or Dp44mT (an ROS gener-
ator) also increased [3H]-thymidine incorporation into
HCASMCs after applying 2.5% hypoxia for 2 to 4 hours.Hypoxia increases the presence of leptin in the nuclei of
HCASMCs
We used confocal microscopy to identify the presence
of leptin in the nuclei of HCASMCs under hypoxia
(Additional file 4: Figure S4). Hypoxia increased leptin
expression (green color) in the nuclei (purple color) of
HCASMCs (red color), which could be inhibited by
Figure 4 Hypoxia-induced leptin expression in HCASMCs is mediated by reactive oxygen species (ROS). (A and B) ROS assay, using a
fluorescence microscope, indicated that hypoxia for 1 hour increased ROS production similarly to that of the exogenous addition of Dp44mT or
AngII. Treatment with NAC (500 μM) or AngII type 1 receptor blocker (ARB; losartan 100 nM) 1 hour before hypoxia significantly blocked the
induction. *P < 0.01 vs. normoxia control. #P < 0.01 vs. 1 h (n = 3).
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tion, the exogenous addition of AngII, Dp44mT, or lep-
tin also increased the presence of leptin in the nuclei of
HCASMCs.
Discussion
Leptin plays an important role in atherosclerosis by
initiating leukocyte and macrophage recruitment to
the endothelial wall. With respect to CVDs, leptin also
has a variety of pro-atherogenic functions. It stimu-
lates the hypertrophy and proliferation of VSMCs and
their production of metalloproteinase. In addition, lep-
tin promotes the production of proliferative and in-
flammatory cytokines, it increases platelet aggregationand enhances the secretion of pro-atherogenic lipoprotein
lipase by cultured human and rodent macrophages [16]
causing endothelial dysfunction by increasing ROS
[29]. Increased leptin level promotes VSMC prolifera-
tion and migration and vascular calcification. The gen-
eration of ROS by leptin reduces the bioavailability of
nitric oxide (NO) in VSMCs by inactivating NO or
eNOS and leads to endothelial dysfunction [30]. With
respect to CVDs, leptin induces hypertension, athero-
sclerosis, myocardial infarction, vascular inflammation,
VSMC hypertrophy and endothelial dysfunction. Thus,
leptin induces phenotypic changes in VSMCs (prolifer-
ation, migration, hypertrophy, and calcification) that
are pro-atherogenic.
Figure 5 Binding activity between leptin and activator protein 1 (AP-1) transcription factor and genetic transcription activity at the
AP-1-binding site of the leptin promoter increase in HCASMCs under hypoxia. (A) Electrophoretic mobility shift assay (EMSA) showed an
increase in binding between leptin and AP-1 in HCASMCs under 2.5% O2 hypoxia. The binding between leptin and AP-1 was suppressed by
SP600125 (25 μM), losartan (100 nM), and NAC (500 μM). (B and C) The luciferase reporter assay revealed that 2.5% O2 hypoxia increased the
transcriptional activity of AP-I to the leptin promoter compared to the leptin mutant. Transcriptional activity was suppressed by SP600125, NAC,
and losartan. Exogenous addition of AngII (10 nM) increased the transcriptional activity of HCASMCs similarly to that of 2.5% O2 hypoxia. *P < 0.01
vs. normoxia control. #P < 0.01 vs. 2 h (n = 3).
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lar function. The expression of leptin is related to the
development of hypoxia in the adipose tissue of obese
individuals. Studies have found that white adipose tissue
becomes hypoxic as size and mass expand due to obesity,
the level of leptin is thus directly related to body weight
or fat [31,32]. The development of hypoxia, furthermore,
initiates and drives the inflammatory response andoxidative stress in the adipose tissue of obese individuals;
this, again, is related to the expression of leptin [33]. The
expression, under hypoxia, of the leptin gene linked to
inflammation suggests a connection between hypoxia and
the inflammatory response. It is well known, after all, that
HIF-1α and leptin regulate the molecular response to hyp-
oxia [34,35]. Under hypoxia, leptin has been found to be
transcriptionally regulated by HIF-1α, with an increase of
Figure 6 AngII, ROS, and the JNK pathway are involved in leptin expression in HCASMCs under hypoxia. (A and B) Under hypoxia, AngII
(10 nM), an ROS generator (Dp44mT; 30 nM)), and a JNK MAPK stimulator (Anisomycin; 20 μM) increased leptin protein expression in HCASMCs.
AngII-induced leptin protein expression could be inhibited by SP600125 (25 μM) and NAC (500 μM). Dp44mT-induced leptin protein expression
could be inhibited by SP600125 (25 μM). However, Anisomycin-induced leptin protein expression could not be inhibited by losartan (ARB; 100
nM) or NAC (500 μM). These results imply that hypoxia-induced leptin expression in HCASMCs is regulated through the JNK pathway, with its
earliest expression coming from treatment with AngII, and then from ROS. *P < 0.01 vs. normoxia control. #P < 0.01 vs. 4 h (n = 3).
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which is a hypoxic transcription factor [36-38]. Moreover,
the synthesis of leptin and vascular endothelial growth fac-
tor (VEGF) under hypoxia reflects the growth of the capil-
lary network and the subsequent enhancement of blood
delivery and tissue oxygenation to hypoxic areas that are
typical responses to low O2. With this in mind, the in-
flammatory response incited by the increased production
of leptin is associated with angiogenesis in adipose tissue
[37-40]. In this light, hypoxia is understood as an initiating
event in adipose tissue dysfunction, followed by fibrosis
and inflammation. Also, obstructive sleep apnea withhypoxia in obese people is associated with insulin resist-
ance, metabolic syndrome, and cardiovascular abnormal-
ities [41,42]. In in vivo studies, intermittent hypoxia has
been found to induce insulin resistance in mice, and this is
accompanied by an up-regulation of leptin gene expres-
sion in adipose tissue [43].
In this study, we identified some findings not previously
reported: (1) that hypoxia induces AngII expression and
ROS generation, causing HCASMC proliferation and mi-
gration; (2) that the JNK pathway specifically mediates
hypoxia-induced leptin expression in HCASMCs; (3) that
hypoxia promotes AngII secretion and ROS generation
Figure 7 Hypoxia increases migration activity of HCASMCs. (A and B) 2.5% O2 hypoxia for 4 h increased migration activity of HCASMCs,
which was inhibited by SP600125 (25 μM), leptin siRNA, NAC (500 μM), or losartan (100 nM). In addition exogenous addition of Dp44mT (30 nM),
leptin, or AngII (10 nM) under normoxia also increased migration activity of HCASMCs. *P < 0.01 vs. normoxia control. #P < 0.01 vs. 4 h (n = 3).
Figure 8 Hypoxia increases proliferation activity of HCASMCs. Incorporation of [3H]Thymidine into HCASMCs increased under 2.5% hypoxia
and exogenous addition of leptin, AngII, or Dp44mT (under normoxia) for 2 to 4 h. Hypoxia-induced incorporation of [3H]Thymidine into
HCASMCs was suppressed by leptin siRNA, losartan, NAC, and SP600125. *P < 0.01 vs.normoxia control. #P < 0.01 vs. hypoxia (n = 6).
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tion in HCASMCs; and (4), that the relationship between
AngII, ROS, leptin, and AP-1 (not HIF-1α) expression in
HCASMCs under hypoxia results in artherogenesis.
The present study yielded similar results to a previous
report that also examined leptin expression in HCASMCs
subjected to hypoxia [23]. Under 2.5% O2 hypoxia, signifi-
cant oxidative stress induced hypoxic signaling (JNK) and
activated leptin expression. Our study identified the JNK
pathway as the mediator of the hypoxia-induced leptin ex-
pression in HCASMCs. The JNK pathway has been re-
ported to mediate the oxidative stress induced by leptin
[24]. Moreover, hypoxia has been shown to stimulate JNK
activation in a variety of cell types including HCASMCs.
JNK mediates signals in response to cytokines and envir-
onmental stress, including oxidative stress. Previous stud-
ies indicated that JNK activation and ROS generation are
immediate responses to hypoxia. Because the JNK path-
way has been shown to be responsible for the hypoxic sig-
naling, we hypothesized that either JNK1 siRNA or an
ROS scavenger (NAC) could effectively attenuate hypoxia-
induced JNK pathway activation.
The phosphorylation of JNK activates the JNK path-
way. In previous studies, increases in JNK tyrosine phos-
phorylation occurred at an early hypoxic exposure time.
In terms of the downstream effect of JNK activation, it is
well documented that hypoxia leads to the activation of
the AP-1 transcriptional factor that participates in cell
response to hypoxia. Similarly, JNK phosphorylation en-
hanced oxidative phosphorylation and signal transduc-
tion to facilitate leptin expression; contrariwise, the JNK
inhibitor, JNK siRNA, and NAC repressed the expression
of leptin.
The relationship among AngII, ROS, and leptin, as
well as their regulatory effects on genetic transcription
in HCASMCs under hypoxia, has not yet been fully de-
fined. AngII has been shown to induce HCASMC prolif-
eration and migration under hypoxia. Hypoxia may
regulate the expression of leptin in HCASMCs, and
AngII may serve as an upstream mediator of leptin. Our
study found that hypoxia-induced AngII secretion stim-
ulated leptin expression, genetic transcription, and
artherogenesis in HCASMCs, which could be effectively
inhibited by ARB. Figure 3A showed that 2.5% hypoxia
rapidly induced an increase in the levels of AngII within
1 h. So hypoxia may directly induce AngII release or
protein synthesis, and indirectly mediated through cleav-
age of pro-AngII via activation of some enzymes. Previ-
ous study indicated that leptin requires AngII and
Endithelin-1 (ET-1) co-stimulation for induction of rat
VSMC hypertrophy [44]. This is achieved by leptin-
induced increases in angiotensinogen, AngII type 1 (AT1)
receptor, prepro- ET-1, and ETA gene expression in rat
VSMCs.Our data also showed that ROS are involved in leptin-
induced artherogenesis. Heightened ROS generation is
closely associated with hypoxia. Studies have reported
that ROS can modulate signaling pathways known to be
involved in HCASMC proliferation and migration, in-
cluding the JNK pathway. Increased production of ROS,
furthermore, promotes HCASMC growth. ROS may be
an upper mediator and a second messenger mediating
intracellular signaling pathways. NAC effectively sup-
pressed hypoxia-induced leptin expression, leptin and
AP-1 binding, leptin-related genetic transcription in
HCASMCs, and artherogenesis.
In different cell types, different MAPK pathways may
be involved in the genetic transcription to leptin. Our
study showed that AP-1, a downstream target of JNK,
may play a role in the transcriptional regulation of lep-
tin. The gel shift assay showed that leptin-DNA binding
activity increased after hypoxia. This effect ceased with
the use of a leptin-mutant plasmid, SP600125, and ARB.
In HCASMCs, leptin- related genetic transcription occurs
through AP-1 binding to the leptin promoter. In fact, the
effects of hypoxia on the leptin promoter activity were
eliminated when the AP-1 binding site was mutated.
Our study also demonstrated that hypoxia increased
the presence of leptin in the nuclei of HCASMCs. This
effect was effectively inhibited by NAC, JNK inhibitor,
and leptin siRNA, indicating a relationship between AngII,
ROS, the JNK pathway, and leptin. In addition, leptin,
Dp44mT, or AngII, added exogenously, also increased the
presence of leptin in the nuclei of HCASMCs.
Conclusion
In conclusion, hypoxia in cultured HCASMCs induces
the expression of AngII and ROS. Ang II, ROS, and the
JNK pathway mediate the induction of leptin expression
with subsequent artherogenesis through increased tran-
scriptional activity in HCASMCs. Artherogenesis in
HCASMCs under hypoxia can be identified by increased
proliferation and migration activity. Hypoxia-induced
AngII expression has similar effects to that of exogen-
ously added AngII and may increase both leptin expres-
sion and transcriptional activity in HCASMCs.
Additional files
Additional file 1: Figure S1. Effect of different degree of hypoxia on
the expression of leptin protein in HCASMCs. (A and B) Leptin protein
expression was measured in HCASMCs subjected to different degree of
hypoxia (10%, 5%, and 2.5% O2) for 4 h. Leptin expression was notably
increased by 2.5% hypoxia for 4 h in comparison to the other hypoxia
conditions. *P < 0.01 vs. normoxia control (n = 3).
Additional file 2: Figure S2. Inhibitory effect of JNK1 siRNA on the
phosphorylation of JNK under hypoxia in HCASMCs. (A and B) JNK1
siRNA inhibited 60% of JNK phosphorylation compared with control
siRNA after 2.5% hypoxia for 2 h. #P < 0.01 vs. control siRNA (n = 3).
Chiu et al. Journal of Biomedical Science  (2015) 22:5 Page 13 of 14Additional file 3: Figure S3. Hypoxia-induced leptin protein expression
is not inhibited by HIF-1α siRNA under hypoxia in HCASMCs. (A and B)
Hypoxia with 2.5% hypoxia increased leptin protein expression in
HCASMCs. HIF-1α siRNA could not inhibit hypoxia-induced leptin protein
expression. *P < 0.01 vs.normoxia control. #P < 0.01 vs. hypoxia (n = 3).
Additional file 4: Figure S4. Hypoxia increases the presence of leptin
in the nuclei of HCASMCs. Hypoxia increased the presence of leptin
(green color) in the nuclei (purple color) of HCASMCs (red color), which
could by inhibited by SP600125, losartan, NAC, and leptin siRNA. In
addition, exogenously addition of AngII, Dp44mT, or leptin under
normoxia also increased the presence of leptin in the nuclei of HCASMCs
(n = 6).
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